Otonomy (OTIC) Stock Price
Otonomy Price
Revenue at Otonomy has contracted by 28.7% per year over the past 5 years to 125,000.00 USD. For Otonomy, the net margin of -40,944.8% is down versus -7,268.5% a few years ago.
Otonomy stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Otonomy over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Otonomy stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Otonomy's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Otonomy Price |
|---|
Otonomy Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Otonomy Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e | 2025e | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | 1.00 | – | – | – | – | – | – | – | 5.00 | 76.00 | 178.00 | 280.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 1,420.00 | 134.21 | 57.30 |
| – | – | – | – | -100.00 | – | – | – | – | – | – | – | -100.00 | -100.00 | -100.00 | -100.00 |
| -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -5.00 | -76.00 | -178.00 | -280.00 |
| -19.00 | -39.00 | -61.00 | -111.00 | -91.00 | -52.00 | -44.00 | -43.00 | -49.00 | -53.00 | -52.00 | -62.00 | -102.00 | -59.00 | 12.00 | – |
| – | – | – | – | -9,100.00 | – | – | – | – | – | – | – | -2,040.00 | -77.63 | 6.74 | – |
| -20.00 | -42.00 | -61.00 | -110.00 | -90.00 | -50.00 | -44.00 | -44.00 | -51.00 | -49.00 | -40.00 | -52.00 | -90.00 | -51.00 | 9.00 | 58.00 |
| 150.00 | 110.00 | 45.24 | 80.33 | -18.18 | -44.44 | -12.00 | – | 15.91 | -3.92 | -18.37 | 30.00 | 73.08 | -43.33 | -117.65 | 544.44 |
| 19.42 | 7.85 | 23.95 | 29.96 | 30.30 | 30.61 | 30.73 | 40.85 | 63.44 | 63.44 | 63.44 | 63.44 | 63.44 | 63.44 | 63.44 | 63.44 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Otonomy generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Otonomy retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Otonomy's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Otonomy has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Otonomy's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Otonomy stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Otonomy Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Otonomy business model & stock analysis
Otonomy SWOT Analysis
Strengths
Otonomy Inc has several strengths that contribute to its success in the market. Firstly, the company has a strong portfolio of innovative products with promising potential in the field of ear therapeutics. This gives Otonomy a competitive edge over its peers. Additionally, Otonomy has a dedicated and experienced research and development team, constantly working on breakthrough advancements. This enables the company to stay ahead in the industry. Another strength of Otonomy is its strong financial position, enabling it to invest in research, marketing, and expansion activities.
Weaknesses
Despite its strengths, Otonomy Inc also faces some weaknesses that can pose challenges. One of these weaknesses is its dependence on a limited number of products for revenue generation. This leaves Otonomy vulnerable to market fluctuations and potential setbacks in product development. Additionally, the company's marketing and brand recognition efforts need improvement, as it faces strong competition from well-established players in the market. It should also focus on enhancing its distribution network to reach a wider customer base.
Opportunities
Otonomy Inc has several opportunities in the industry that it can capitalize on. The increasing prevalence of hearing disorders and related conditions presents a significant market opportunity for the company's ear therapeutics. Otonomy can also explore strategic partnerships with healthcare providers and institutions to enhance its market presence and access to patients. Moreover, the growing adoption of telemedicine and digital health platforms provides Otonomy with an opportunity to expand its reach and offer remote consultations and support to patients.
Threats
Like any other company, Otonomy Inc faces threats that can impact its growth and profitability. One of the major threats is the presence of intense competition from large pharmaceutical companies that have extensive resources and established brand names. Otonomy needs to continuously innovate and distinguish itself to compete effectively. Moreover, regulatory challenges and strict compliance requirements pose a threat to the company's product development and commercialization efforts. Additionally, any unforeseen economic downturn or global health crisis can negatively impact Otonomy's operations and financial performance.
Otonomy Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Otonomy historical P/E ratio, EBIT multiple, and P/S ratio
Otonomy annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Otonomy shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Otonomy Dividend History
1 years of dividend payments
Otonomy Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 7/24/2023 | -0.12USD | - | 0.00USD | - | 2023 Q2 |
| 5/8/2023 | -0.11USD | - | 0.00USD | - | 2023 Q1 |
| 2/27/2023 | -0.16USD | - | 0.00USD | - | 2022 Q4 |
| 11/10/2022 | -0.19USD | - | 0.00USD | - | 2022 Q3 |
| 7/25/2022 | -0.20USD | - | 0.00USD | - | 2022 Q2 |
| 5/9/2022 | -0.21USD | - | 0.00USD | - | 2022 Q1 |
| 2/28/2022 | -0.19USD | - | 0.00USD | - | 2021 Q4 |
| 11/10/2021 | -0.19USD | - | 16,920.00USD | - | 2021 Q3 |
| 8/4/2021 | -0.18USD | - | 31,718.00USD | - | 2021 Q2 |
| 5/11/2021 | -0.21USD | - | 33,829.00USD | - | 2021 Q1 |
Otonomy shareholder structure
| % | Name |
|---|---|
7.48980% | |
0.97284% | |
0.26182% | |
0.22972% | |
0.17231% | |
0.12139% |
Otonomy Executives and Management Board
9 members · avg. age 60 · 33 % women
Mr. Paul Cayer (60)
President, Chief Financial and Business Officer, Secretary
1.85 M USD
Dr. David Weber (62)
Director · since 2010
Dr. Jay Lichter (60)
Independent Chairman of the Board · since 2010
Ms. Vickie Capps (60)
Independent Director
Mr. Iain Mcgill (49)
Independent Director
Dr. James Breitmeyer (68)
Independent Director
Mr. Theodore Schroeder (67)
Independent Director
Otonomy Supply Chain
Otonomy Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.03 | -0.39 | 0.68 | ||
| 2 | -0.13 | -0.46 | 0.61 | ||
| 3 | 0.35 | -0.04 | 0.57 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.53 | 0.56 | -0.50 |
Frequently asked questions about Otonomy
The main competitors of Otonomy Inc in the market include various pharmaceutical and biotechnology companies involved in the development of innovative therapies for ear-related conditions. Some prominent competitors of Otonomy Inc include Novartis AG, Pfizer Inc, and Johnson & Johnson. These companies also strive to enhance treatment options and improve patient outcomes in the field of otology and related disorders.
The business model of Otonomy Inc focuses on developing and commercializing innovative treatments for diseases and disorders of the ear. The company utilizes its proprietary technology platform to design and deliver drug therapies directly into the ear, targeting specific areas to address conditions such as hearing loss, tinnitus, and ear infections. By focusing on the otology market, Otonomy aims to provide patients with improved treatment options that are more effective and convenient. With a strong emphasis on research and development, Otonomy Inc strives to bring breakthrough therapies to market and make a positive impact on the lives of individuals with ear-related conditions.
Otonomy Inc is primarily active in the biotechnology and pharmaceutical industries.
Otonomy Inc is a biopharmaceutical company specializing in developing and commercializing innovative therapeutics for diseases affecting the ear. Founded in 2008, the company has focused on treating conditions such as Ménière's disease, chronic otitis media, and hearing loss. Otonomy utilizes its proprietary technology, called OTO-313, to deliver targeted drug treatments to the ear, aiming to restore normal function and improve patient outcomes. Through its dedicated research and development efforts, Otonomy aims to address the unmet medical needs of individuals suffering from various ear-related disorders. This commitment has positioned Otonomy as a leader in the field of otology.
Some significant milestones achieved by Otonomy Inc include the FDA approval of their product Otiprio, a treatment for pediatric patients with middle ear effusion, the successful completion of Phase 3 clinical trials for their product OTIVIDEX, a potential treatment for Meniere's disease, and the initiation of Phase 1/2 clinical trials for their product OTO-313, targeting tinnitus. Otonomy Inc has also entered into strategic partnerships and collaborations with companies like AGTC and CFFT to further advance their pipeline and enhance their expertise in gene therapy and cystic fibrosis. These accomplishments demonstrate Otonomy Inc's commitment to developing innovative solutions for hearing and balance disorders.
Otonomy Inc is primarily present in the United States.
Otonomy Inc represents a strong corporate philosophy centered around advancing hearing healthcare. They are committed to improving the lives of patients with ear and hearing disorders by developing innovative treatments. Otonomy Inc values patient-centricity, scientific excellence, and collaboration with healthcare professionals. They strive to deliver safe and effective therapies for various ear conditions, such as Meniere's disease and pediatric ear infections. With their dedication to research and development, Otonomy Inc aims to address unmet medical needs and enhance the quality of life for individuals suffering from ear-related ailments.
7 analysts currently rate the Otonomy stock: 6 recommend buying, 1 holding and 0 selling.
The Otonomy share (OTIC) is listed on 5 stock exchanges, including: NASDAQ (OTIC), Frankfurt (7OT.F), München (7OT.MU), Düsseldorf (7OT.DU), SIX (Zürich) (7OT.SW).
Otonomy Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of ear diseases. The company was founded in 2008 and is headquartered in San Diego, California. The company is divided into two business segments: Ear and Neurology. In the Ear segment, the company focuses on developing innovative products for the treatment of ear diseases such as hearing loss, tinnitus, and ear infections. In the Neurology segment, the company is dedicated to treating central nervous system disorders such as multiple sclerosis and migraine. One of Otonomy Inc's main products is OTIPRIO, an antibiotic for the treatment of acute middle ear infection in children. It is injected directly into the affected ear and reduces the need for systemic antibiotic therapy. OTIPRIO is the first and only product approved by the FDA for treating ear infections in a doctor's office. Another important product of Otonomy Inc is OTIVIDEX, a medication for treating patients with Meniere's disease, an inner ear disorder that causes dizziness, hearing loss, and ringing in the ears. OTIVIDEX has been studied in a clinical trial and has shown significant benefits compared to placebo. The company also has other products in development, including OTO-313, a medication for treating tinnitus, and OTO-413, a medication for treating hearing loss. Both products are in clinical trials. Otonomy Inc has a strong pipeline of products in development and is continuously working to expand its product range. This strategy is aimed at ensuring the long-term growth of the company and expanding treatment options for patients with ear and neurological diseases. The company's financing is primarily through the sale of stocks and investments from venture capital funds. The company went public in 2014. Overall, Otonomy Inc's business model is focused on developing and successfully commercializing innovative products for the treatment of ear and neurological diseases. The company relies on a strong pipeline of products in development to ensure long-term growth.
The revenue cannot currently be calculated for Otonomy.
The profit cannot currently be calculated for Otonomy.
The P/E ratio cannot be calculated for Otonomy at the moment.
The P/S cannot be calculated for Otonomy currently.
The Eulerpool Quality Score for Otonomy is 2/10.
The ISIN of Otonomy is US68906L1052. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Otonomy is A119VZ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Otonomy is OTIC. The ticker symbol is used to trade Otonomy shares on the stock exchange.
Otonomy is assigned to the 'Health' sector.
The dividends of Otonomy are distributed in USD.
Otonomy stock
Otonomy Peer Group
Otonomy Ticker
Otonomy FIGI
All fundamentals and in-depth analysis of Otonomy
Our stock analysis for Otonomy stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Otonomy. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.